Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
29 studies found for:    " November 21, 2011":" December 21, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" November 21, 2011":" December 21, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Safety and Immunogenicity Study of HIV-MAG Vaccine +/- IL-12 and Ad35-GRIN/ENV in HIV-uninfected Volunteers
Condition: HIV Infections
Interventions: Biological: HIV-MAG (3,000mcg);   Biological: GENEVAX® IL-12 (100mcg);   Biological: GENEVAX® IL-12 (1000mcg);   Biological: Ad35-GRIN/ENV
2 Completed Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence
Condition: HIV Infection
Interventions: Drug: Immediate ARV treatment initiation with TDF/FTC/EFV;   Other: South African recommendation guided ARV (TDF/FTC/EFV) initiation
3 Recruiting Use of Incentives to Retain Drug Users in HIV Therapy
Condition: HIV Infection
Intervention: Other: monetary reinforcer
4 Withdrawn Evaluating the Safety of Tenofovir Vaginal Gel in HIV-Uninfected Pregnant Women
Condition: HIV Infections
Interventions: Drug: 1% tenofovir gel;   Drug: Placebo gel
5 Active, not recruiting Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: VRC rAd5 vaccine (rAd5 gag-pol/env A/B/C);   Biological: rAd5 env A;   Biological: rAd5 env B;   Biological: rAd5 env C;   Biological: rAd5 gag-pol;   Biological: Placebo Vaccine
6 Completed
Has Results
Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: E/C/F/TDF;   Drug: E/C/F/TAF Placebo;   Drug: E/C/F/TAF;   Drug: E/C/F/TDF Placebo
7 Completed
Has Results
Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: NNRTI;   Drug: FTC/TDF;   Drug: Stribild
8 Completed Early HIV Therapy in Patients With High CD4 Cell Counts
Condition: HIV
Interventions: Drug: Standard ART;   Drug: Study-Provided ART
9 Active, not recruiting Evaluating the Safety of Immediate Versus Deferred Isoniazid Preventive Therapy Among HIV-Infected Pregnant Women
Conditions: HIV Infections;   Tuberculosis
Interventions: Drug: Isoniazid (INH);   Drug: Placebo for isoniazid (INH)
10 Recruiting Evaluation of a Tailored Virtual Intervention to Empower Persons Living With HIV for Therapy Self-management
Condition: HIV
Intervention: Behavioral: VIH-TAVIE
11 Terminated Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Condition: HIV-1 Infection
Interventions: Drug: BMS-986001;   Drug: Placebo matching with BMS-986001;   Drug: Efavirenz;   Drug: Lamivudine;   Drug: Tenofovir
12 Completed Men of African American Legacy Empowering Self
Condition: HIV
Interventions: Behavioral: Men of African American Legacy Empowering Self;   Behavioral: Standard HIV Education & Risk Reduction
13 Completed American Ginseng to Improve HIV-Associated Fatigue: A Randomized, Placebo-Controlled, Parallel Design, Multiple-Dose Clinical Trial
Condition: HIV/AIDS-associated Fatigue
Interventions: Drug: American ginseng;   Dietary Supplement: Placebo for American ginseng
14 Completed
Has Results
Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection
Conditions: HIV Infections;   Hepatitis C
Interventions: Drug: Pegylated-Interferon Alfa 2b (PEG-IFN);   Drug: Ribavirin (RBV);   Drug: Boceprevir (BOC)
15 Completed
Has Results
A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects
Condition: Infection, Human Immunodeficiency Virus
Intervention: Drug: Dolutegravir
16 Completed Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and Ethinylestradiol
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: Ortho-Cyclen;   Drug: Dolutegravir;   Drug: Placebo
17 Completed Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors
Condition: HIV-1 Infection
Interventions: Drug: Isentress® (Raltegravir, 400 mg every 12 hours);   Drug: Isentress® (Raltegravir, 400 every 12 hours)
18 Active, not recruiting A Smoking Cessation Trial in HIV-infected Patients in South Africa
Conditions: Smoking Cessation;   HIV
Interventions: Drug: Nicotine;   Behavioral: Intensive Counseling
19 Active, not recruiting Lipopeptide Immunisation With GTU-multiHIV Trial
Condition: HIV-1 Infection
Interventions: Biological: Placebos of GTU-multiHIV B and LIPO-5 vaccines;   Biological: GTU-multHIV B vaccine and LIPO-5 vaccine
20 Completed Men Together Making a Difference: Reducing HIV/STD Risk Behavior Among South African Men
Conditions: Human Immunodeficiency Virus Infection;   Sexually Transmitted Diseases
Interventions: Behavioral: Men Making a Difference HIV/STD Risk Reduction Intervention;   Behavioral: Health Promotion Control

   Previous Page Studies Shown (1-20) Next Page (21-29) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.